Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 2
1977 2
1978 2
1980 1
1982 1
1984 1
1985 2
1986 1
1988 2
1990 2
1992 1
1993 2
1995 2
1999 1
2002 1
2006 1
2007 1
2010 3
2011 3
2013 2
2014 1
2017 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Central nervous system lymphoma.
Lister A, Abrey LE, Sandlund JT. Lister A, et al. Hematology Am Soc Hematol Educ Program. 2002:283-96. doi: 10.1182/asheducation-2002.1.283. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446428 Review.
Central nervous system involvement with malignant lymphoma whether primary or secondary is an uncommon but not rare complication observed in the management of patients with hematological malignancy. ...John Sandlund reviews the success of sequential clinical trials of over …
Central nervous system involvement with malignant lymphoma whether primary or secondary is an uncommon but not rare complication observed …
Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.
Laningham FH, Kun LE, Reddick WE, Ogg RJ, Morris EB, Pui CH. Laningham FH, et al. Neuroradiology. 2007 Nov;49(11):873-88. doi: 10.1007/s00234-007-0300-7. Epub 2007 Oct 9. Neuroradiology. 2007. PMID: 17924103 Free PMC article. Review.
The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. ...
The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS mo …
Central nervous system leukemia.
Bleyer WA. Bleyer WA. Pediatr Clin North Am. 1988 Aug;35(4):789-814. doi: 10.1016/s0031-3955(16)36510-5. Pediatr Clin North Am. 1988. PMID: 3047654 Review.
The improved outcome in intellectual and academic performance in the NCI-191/CCG-134P conjoint trial of the CCSG and the Pediatric Branch described above (see section of Presymptomatic CNS Therapy) appears to confirm this observation. Whether triple IT chemotherapy will ha …
The improved outcome in intellectual and academic performance in the NCI-191/CCG-134P conjoint trial of the CCSG and the Pediatric Branch de …
Comprehensive craniospinal radiation for controlling central nervous system leukemia.
Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Walker GV, et al. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1119-25. doi: 10.1016/j.ijrobp.2014.08.004. Int J Radiat Oncol Biol Phys. 2014. PMID: 25539370 Free PMC article.
Among 149 patients with a total of 233 deficits, resolution was observed in 34 deficits (15%), improvement in 126 deficits (54%), stability in 34 deficits (15%), and progression in 39 deficits (17%). ...
Among 149 patients with a total of 233 deficits, resolution was observed in 34 deficits (15%), improvement in 126 deficits (54%), sta …
Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Zhu Y, Zhu Y, Miao L, Jia T, Mao J, Xue L, Wang Y. Zhu Y, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231165866. doi: 10.1177/15330338231165866. Technol Cancer Res Treat. 2023. PMID: 36959735 Free PMC article.
INTRODUCTION: Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL), with a poor prognosis and high relapse rate. ...The …
INTRODUCTION: Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients …
Intrathecal methotrexate versus central nervous system leukemia.
Bleyer WA. Bleyer WA. Cancer Drug Deliv. 1984;1(2):157-67. doi: 10.1089/cdd.1984.1.157. Cancer Drug Deliv. 1984. PMID: 6399986 Review.
The pharmacokinetics of IT MTX are then presented and the review is concluded with observations on the importance of the dosage regimen....
The pharmacokinetics of IT MTX are then presented and the review is concluded with observations on the importance of the dosage regim …
PPARG, GNG12, and CD19 are potential independent predictors of central nerve recurrence in childhood acute lymphoblastic leukemia.
Zhang S, Tu Y, Lai H, Chen H, Tu H, Li J. Zhang S, et al. Hematology. 2023 Dec;28(1):2182169. doi: 10.1080/16078454.2023.2182169. Hematology. 2023. PMID: 36861936
OBJECTIVE: To identify biomarkers that can predict the recurrence of the central nervous system (CNS) in children with acute lymphoblastic leukemia (ALL). ...Then, we constructed a Nomogram which had a concordance index of survival prediction of 0.791(95%CI= 0.779-0 …
OBJECTIVE: To identify biomarkers that can predict the recurrence of the central nervous system (CNS) in children with acute lymphobl …
Inhibition of Integrin αvβ3-FAK-MAPK signaling constrains the invasion of T-ALL cells.
Huang L, Zhu Y, Kong Q, Guan X, Lei X, Zhang L, Yang H, Yao X, Liang S, An X, Yu J. Huang L, et al. Cell Adh Migr. 2023 Dec;17(1):1-14. doi: 10.1080/19336918.2023.2191913. Cell Adh Migr. 2023. PMID: 36944577 Free PMC article.
Firstly, we performed quantitative real-time PCR to assess medullary expression of integrin beta3(ITGB3) in T-ALL patients and high ITGB3 expression was relevant with the central nervous system leukemia(CNSL) incidence. Decreasing of cell invasion was …
Firstly, we performed quantitative real-time PCR to assess medullary expression of integrin beta3(ITGB3) in T-ALL patients and high ITGB3 ex …
Interactome based identification and validation of prefoldin 5-α for prognosing CNS leukemia in B-ALL patients.
Xavier T, Vijayachandran LS, Chandran R, Mony U, Augustine A, Sidharthan N, Ganapathy R, Keechilat P, Sundaram KR, Menon KN. Xavier T, et al. Sci Rep. 2022 Sep 15;12(1):15491. doi: 10.1038/s41598-022-19489-7. Sci Rep. 2022. PMID: 36109530 Free PMC article.
We report here the identification and validation of prefoldin 5-alpha (PFDN5-alpha) for the first time as prognostic biomarker for prediction of central nervous system (CNS) leukemia of B cell acute lymphoblastic leukemia (B-ALL) origin. ...Thus, using interactome studies, …
We report here the identification and validation of prefoldin 5-alpha (PFDN5-alpha) for the first time as prognostic biomarker for predic …
The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.
Tang YT, Jiang F, Guo L, Si MY, Jiao XY. Tang YT, et al. J Neurooncol. 2013 May;112(3):329-38. doi: 10.1007/s11060-013-1066-x. Epub 2013 Feb 12. J Neurooncol. 2013. PMID: 23400753
VEGF-A acts by binding to its membrane receptors R1 and R2 present in soluble forms (sVEGFR1, sVEGFR2) with different functions. sVEGFR could inhibit VEGF-A bioactivities, associated with favorable prognosis in solid tumors. However, its role is obscure in central nervo …
VEGF-A acts by binding to its membrane receptors R1 and R2 present in soluble forms (sVEGFR1, sVEGFR2) with different functions. sVEGFR coul …
43 results